This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ellis, L. M. Articles by Hicklin, D. J. Search for Related Content PubMed PubMed Citation Articles by Ellis, L. M. Articles by Hicklin, D. J.

Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy

Authors' Affiliations: ¹ Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas and ² Oncology Discovery, Schering-Plough Research Institute, Schering-Plough Corporation, Kenilworth, New Jersey

Requests for reprints: Lee M. Ellis, M. D. Anderson Cancer Center, P.O. Box 301402, Houston, TX 77230-1402. Phone: 713-792-6926; Fax: 713-792-4689; E-mail: lellis{at}mdanderson.org.

Abstract

Vascular endothelial growth factor (VEGF)–targeted therapy has become an important treatment option for the management of a number of human malignancies. Unfortunately, a significant number of patients do not respond to VEGF-targeted therapy when used as a single agent or in combination with chemotherapy. Furthermore, the duration of benefit from VEGF-targeted therapy can be relatively short (weeks to months). Ultimately, the vast majority of patients who initially respond to therapy will develop resistance. To date, the molecular and cellular mechanisms associated with resistance to VEGF-targeted agents are poorly understood. The mechanisms of action of anti-VEGF therapy are diverse, and it is entirely possible that resistance mechanisms are similarly diverse and depend on the tumor type. A better understanding of these mechanisms will help in the selection of those patients that are more likely to benefit from VEGF-targeted therapy and also provide for the rational development of therapies that circumvent or overcome resistance.

This article has been cited by other articles:

				P. Y. Wen, A. D. Norden, and J. Drappatz Antiangiogenic Therapies for Malignant Gliomas ASCO Educational Book, January 1, 2009; 2009(1): 113 - 117. [Abstract] [Full Text] [PDF]